Abstract:Objective: To evaluate the safety and long-term efficacy of melphalan (Mel) instead of cyclophosphamide (Cy) in the modified busulfan/cyclophosphamide (Bu/Cy) regimen as a novel myeloablative conditioning regimen for patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Methods: The clinical data of 76 patients with acute myeloid leukemia undergoing allogeneic HSCT from November 2007 to October 2011 were retrospectively analyzed, of which 32 patients received Bu +Mel +Fludarabine(Flu) +Cytarabine(Ara-C) （BMFA）regimen（Bu 3.2mg· kg-1 · d-1 by vein, -8, -7,-6d; Mel 140mg·m-2·d-1, -5d; Flu 30mg·m-2·d-1，-4, -3, -2d; Ara-C 2g·m-2·d-1. -4, -3, -2d）, 44 cases received Bu+ Cy +Flu +Ara-C（BCFA）as modified Bu/Cy regimen (Bu 3.2mg· kg-1 · d-1 by vein, -9,-8, -7d; Cy 50mg· kg-1· d-1，-6, -5d; Flu 30mg·m-2·d-1，-4, -3, -2d; Ara-C 2g·m-2·d-1. -4, -3, -2d ). Anti-thymocyte globulin (ATG) was added to the haploid transplantation and unrelated donor transplant conditioning regimen. Both groups of patients have treated with Cyclosporine A (CsA)/ Tacrolimus (FK506) + short-course methotrexate (MTX)±mycophenolate mofetil (MMF) for graft-versus-host disease (GVHD) prevention. Regimen-related toxicity, engraftment rates, GVHD, and Long-term outcome including relapse, non-relapse mortality (NRM), disease-free survival (DFS), and overall survival (OS) were compared between the two groups. Results: Both groups of patients achieved neutrophil engraftment after transplantation. The incidence of grade Ⅲ-Ⅳ° oral mucositis and diarrhea in the BMFA group was higher than in the BCFA group (P=0.016, P=0.028). The incidence of Ⅱ~Ⅳ° acute GVHD in the BMFA group was also higher than in the BCFA group (37.5% vs. 15.9%，P=0.032). There was no significant difference in the incidence of chronic GVHD between the two groups. With a median follow-up of 97.5 months (2-131months), the cumulative incidence of relapse at 100 months in the BMFA group was lower than in the BCFA group (9.37% vs. 27.7%, P=0.055), and the incidence of NRM in BMFA group was 31.7% and 13.8% in BCFA group (P=0.076)．The OS were (59.0±8.8)% and(59.7±7.6)% (P=0.778)， and DFS were((58.7±8.8)％ and(60.0±7.5)％ (P=0.786) were comparable between BMFA group and BCFA group. In the BMFA group， univariate analysis showed that III-IV° oral mucositis，III-IV° diarrhea, and II-IV°aGVHD were risk factors for NRM (P values, 0.015, 0.015, 0.006, respectively), multivariate analysis showed that II~IV°aGVHD was an independent risk factor for NRM（P=0.025）. Conclusion: The conditioning regimen of melphalan instead of cyclophosphamide for allogeneic HSCT of acute myeloid leukemia has a low relapse rate. In the long-term follow-up, DFS and OS were similar to those of the modified Bu/Cy regimen. However, the prevention of regimen-related toxicity and the treatment and intervention of acute GVHD should be considered to reduce non-relapse mortality. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients

Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Busulfan Combined with Increased-Dose of Fludarabine As Conditioning Regimen for Allogeneic Stem Cell Transplantation in Intermediate and High-Risk Acute Myeloid Leukemia

Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Fludarabine and Busulfan As a Reduced Intensity Myeloablative Conditioning Regimen for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

Allogeneic Peripheral Blood Stem Cell Transplantation Using a Low Toxicity Conditioning Regimen with Fludarabine and Busulfan for 13 Patients with Hematological Malignancies

Reduced‐intensity conditioning with fludarabine/busulfan versus fludarabine/low‐dose melphalan in patients with non‐Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation

Fludarabine and Busulfan As a Reduced-Toxicity Myeloablative Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia Patients.

Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients with Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation A Single Arm Pilot Consort Study

Combination of Busulfan with Increased-Dose of Fludarabine As Conditioning Regimen for MDS and MDS-AML Patients with Allo-Hsct

A Myeloablative Conditioning Regimen with Fludarabine Demonstrates Good Results in UCBT with Hematologic Malignancies, Especially Acute Lymphoblastic Leukemia

Reduced-Intensity Conditioning Therapy with Fludarabine, Idarubicin, Busulfan and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Control Study of Fludarabine Instead of Cyclophosphamide in Modified Busulfan-Cyclophosphamide As a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Acute Leukemia

Retrospective Comparison of Fludarabine in Combination with Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia.

Clinical research of allogeneic hematopoietic stem cell transplantation using conditioning regimen with fludarabine and busulfan for leukemia

Comparison of fludarabine‐based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry‐based study

Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report